经典Wnt信号:红细胞生成的保护者与威胁
本文综述了Wnt/β-catenin信号在健康红细胞生成及骨髓增生异常综合征(MDS)中的作用。Wnt/β-catenin慢性激活与MDS形成及向急性髓系白血病转化相关,但该通路对稳态红细胞生成非必需,而对骨髓损伤和贫血时的应激性红细胞生成至关重要。靶向该通路治疗MDS可能 deregulate 应激性红细胞生成并加重贫血。
要点
- Wnt/β-catenin慢性激活参与MDS形成及向白血病转化。
- Wnt/β-catenin对稳态红细胞生成非必需,但为应激性红细胞生成所必需。
- 靶向Wnt/β-catenin治疗MDS可能加重贫血。
核心结论
- Wnt/β-catenin信号在MDS中慢性激活驱动疾病形成和白血病转化,但靶向该通路可能损害应激性红细胞生成并加重贫血。
研究设计与样本
- 本文为综述,汇总了关于Wnt/β-catenin信号在健康红细胞生成和MDS中作用的最新及已确立见解。
主要发现
- Wnt/β-catenin慢性激活与MDS形成相关,并近期被赋予驱动MDS向急性髓系白血病转化的作用。
- Wnt/β-catenin对稳态红细胞生成非必需,但其活性对于骨髓损伤和贫血时的应激性红细胞生成至关重要。
- 在MDS中操纵Wnt/β-catenin信号可能 deregulate 应激性红细胞生成,甚至增加贫血严重程度。
临床怎么用
- 靶向Wnt/β-catenin治疗MDS时需考虑对应激性红细胞生成的潜在影响,并监测贫血加重。
局限性
- Wnt/β-catenin在健康造血中的控制了解甚少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloid dysplastic syndrome (MDS) reflects a preleukemic bone marrow (BM) disorder with limited treatment options and poor disease survival. As only a minority of MDS patients are eligible for curative hematopoietic stem cell transplantation, there is an urgent need to develop alternative treatment options. Chronic activation of Wnt/β-catenin has been implicated to underlie MDS formation and recently assigned to drive MDS transformation to acute myeloid leukemia. Wnt/β-catenin signaling therefore may harbor a pharmaceutical target to treat MDS and/or prevent leukemia formation. However, targeting the Wnt/β-catenin pathway will also affect healthy hematopoiesis in MDS patients. The control of Wnt/β-catenin in healthy hematopoiesis is poorly understood. Whereas Wnt/β-catenin is dispensable for steady-state erythropoiesis, its activity is essential for stress erythropoiesis in response to BM injury and anemia. Manipulation of Wnt/β-catenin signaling in MDS may therefore deregulate stress erythropoiesis and even increase anemia severity. Here, we provide a comprehensive overview of the most recent and established insights in the field to acquire more insight into the control of Wnt/β-catenin signaling in healthy and inefficient erythropoiesis as seen in MDS.
引用
- Krimpenfort RA, Nethe M. Canonical Wnt: a safeguard and threat for erythropoiesis. Blood Adv. 2021. PMID: 34516644. doi:10.1182/bloodadvances.2021004845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。